
- The New England Journal of Medicine | Research & Review Articles …- 2 days ago · The New England Journal of Medicine (NEJM) is a weekly general medical journal that publishes new medical research and review articles, and editorial opinion on a wide … 
- Tarlatamab in Small-Cell Lung Cancer after Platinum-Based …- Jun 2, 2025 · Tarlatamab, a bispecific delta-like ligand 3–directed T-cell engager immunotherapy, received accelerated approval for the treatment of patients with previously treated small-cell … 
- Imlunestrant with or without Abemaciclib in Advanced Breast Cancer- Dec 11, 2024 · In a phase 3, open-label trial, we enrolled patients with ER-positive, human epidermal growth factor receptor 2 (HER2)–negative advanced breast cancer that recurred or … 
- Antibiotic Treatment for 7 versus 14 Days in Patients with …- Nov 20, 2024 · Bloodstream infections are associated with substantial morbidity and mortality. Early, appropriate antibiotic therapy is important, but the duration of treatment is uncertain. In … 
- Phase 3 Trial of the DPP-1 Inhibitor Brensocatib in Bronchiectasis- Apr 23, 2025 · In bronchiectasis, neutrophilic inflammation is associated with an increased risk of exacerbations and disease progression. Brensocatib, an oral, reversible inhibitor of dipeptidyl … 
- Lepodisiran - The New England Journal of Medicine- Mar 30, 2025 · Elevated lipoprotein(a) concentrations are associated with atherosclerotic cardiovascular disease. The safety and efficacy of lepodisiran, an extended-duration, small … 
- Phase 3 Trial of Semaglutide in Metabolic Dysfunction–Associated ...- Apr 30, 2025 · Semaglutide, a glucagon-like peptide-1 receptor agonist, is a candidate for the treatment of metabolic dysfunction–associated steatohepatitis (MASH). In this ongoing phase … 
- Structured Exercise after Adjuvant Chemotherapy for Colon Cancer- Jun 1, 2025 · In this phase 3, randomized trial conducted at 55 centers, we assigned patients with resected colon cancer who had completed adjuvant chemotherapy to participate in a … 
- Zongertinib in Previously Treated - The New England Journal of …- Apr 28, 2025 · Innovative oral targeted therapies are warranted for patients with human epidermal growth factor receptor 2 (HER2)–mutant non–small-cell lung cancer (NSCLC). Zongertinib is … 
- Xenotransplantation of a Porcine Kidney for End-Stage Kidney …- Feb 7, 2025 · Kidney transplantation has become the ideal standard of care for end-stage kidney disease, but organ shortage remains critical. 1 One promising approach to address this critical …